KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biogen (BIIB) Change in Receivables (2016 - 2025)

Biogen (BIIB) has 17 years of Change in Receivables data on record, last reported at -$27.8 million in Q4 2025.

  • For Q4 2025, Change in Receivables rose 70.64% year-over-year to -$27.8 million; the TTM value through Dec 2025 reached -$102.7 million, up 53.8%, while the annual FY2025 figure was -$102.7 million, 53.8% up from the prior year.
  • Change in Receivables reached -$27.8 million in Q4 2025 per BIIB's latest filing, up from -$70.7 million in the prior quarter.
  • Across five years, Change in Receivables topped out at $200.4 million in Q4 2022 and bottomed at -$174.3 million in Q2 2021.
  • Average Change in Receivables over 5 years is -$25.4 million, with a median of -$37.4 million recorded in 2021.
  • Peak YoY movement for Change in Receivables: plummeted 673.36% in 2021, then skyrocketed 577.18% in 2023.
  • A 5-year view of Change in Receivables shows it stood at -$167.0 million in 2021, then surged by 220.0% to $200.4 million in 2022, then tumbled by 168.76% to -$137.8 million in 2023, then surged by 31.28% to -$94.7 million in 2024, then skyrocketed by 70.64% to -$27.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Receivables were -$27.8 million in Q4 2025, -$70.7 million in Q3 2025, and $66.2 million in Q2 2025.